Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A function of CD10 on bone marrow stroma

S E Delikat1, D W Galvani, M Zuzel

  • 1Department of Haematolology, royal Liverpool University Hospital.

British Journal of Haematology
|July 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Effects of Interferon Alpha Therapy on Oncogene Expression in Chronic Granulocytic Leukaemia.

Leukemia & lymphoma·2016
Same author

Why Does α-Interferon Work in Chronic Granulocytic; Leukaemia?

Leukemia & lymphoma·2016
Same author

Autocrine VEGF mediates the antiapoptotic effect of CD154 on CLL cells.

Leukemia·2005
Same author

In vitro procoagulant and anticoagulant properties of Naja naja naja venom.

Toxicon : official journal of the International Society on Toxinology·2003
Same author

A complication of hip surgery.

Postgraduate medical journal·2003
Same author

The biology of hairy cells.

Best practice & research. Clinical haematology·2003
Same journal

Response-adapted chimeric antigen receptor T cell (CAR-T)-sparing consolidation radiotherapy in high-risk large B-cell lymphoma (LBCL): Results of the prospective RESTART protocol.

British journal of haematology·2026
Same journal

Prospective, multicentre phase II study to evaluate the clinical benefit of reduced-dose lenalidomide and dexamethasone based on frailty stratification in elderly, unfit patients with newly diagnosed multiple myeloma.

British journal of haematology·2026
Same journal

Real-world effectiveness and safety of acalabrutinib in chronic lymphocytic leukaemia: Multicentre experience.

British journal of haematology·2026
Same journal

Novel germline GATA1s-generating variant associates with somatic STAG2 variants in hypoplastic myelodysplastic neoplasm.

British journal of haematology·2026
Same journal

The Endothelial Activation and Stress Index (EASIX) at diagnosis is associated with survival in primary central nervous system lymphoma.

British journal of haematology·2026
Same journal

Hyperlactataemia in lymphoma-associated haemophagocytic lymphohistiocytosis: Linked to monocytic glycolysis and adverse prognosis.

British journal of haematology·2026
See all related articles

Bone marrow stromal cells use CD10 (neutral endopeptidase) to degrade interleukin-1 beta (IL-1 beta). This finding suggests CD10 regulates IL-1 beta

Area of Science:

  • Immunology
  • Cell Biology
  • Hematology

Background:

  • Bone marrow (BM) stromal cells express CD10 (cALLA), a neutral endopeptidase (NEP-24.11).
  • The precise function of CD10 in BM stroma remains unclear.
  • NEP-24.11 is known to degrade various substrates, including interleukin-1 beta (IL-1 beta).

Purpose of the Study:

  • To investigate the hypothesis that CD10 on BM stromal cells degrades IL-1 beta.
  • To explore the role of CD10 in regulating IL-1 beta's effects on stromal cell proliferation.

Main Methods:

  • Utilized a CD10-positive BM stromal cell line (L2AK) that proliferates in response to IL-1 beta.
  • Assessed IL-1 beta-induced [3H]thymidine incorporation in L2AK cells.
  • Examined the effect of the CD10 inhibitor phosphoramidon on IL-1 beta dose-response.

Related Experiment Videos

Main Results:

  • IL-1 beta significantly enhanced [3H]thymidine incorporation by L2AK cells in a dose-dependent manner.
  • The addition of phosphoramidon potentiated the IL-1 beta effect by 10-fold, indicated by a left shift in the dose-response curve.
  • These findings demonstrate that CD10 on BM stromal cells can degrade IL-1 beta.

Conclusions:

  • CD10 expressed by bone marrow stromal cells possesses the enzymatic activity to degrade IL-1 beta.
  • Stromal CD10 likely provides a local regulatory mechanism for the biological activity of IL-1 beta.
  • This suggests a potential role for CD10 in controlling the local microenvironment and growth factor signaling within the bone marrow.